Oruka Therapeutics, Inc.
ORKA
$68.44
$1.512.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -116.25M | -105.43M | -109.24M | -107.59M | -105.26M |
| Total Depreciation and Amortization | 110.00K | 83.00K | 73.50K | 64.50K | 45.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.21M | 19.70M | 20.37M | 21.64M | 18.63M |
| Change in Net Operating Assets | 2.01M | -2.56M | -891.30K | -10.02M | 2.79M |
| Cash from Operations | -90.92M | -88.21M | -89.69M | -95.91M | -83.80M |
| Capital Expenditure | -269.00K | -209.00K | -181.20K | -253.20K | -219.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -153.78M | -96.54M | -434.51M | -312.16M | -317.05M |
| Cash from Investing | -154.05M | -96.75M | -434.69M | -312.41M | -317.27M |
| Total Debt Issued | -- | -- | 2.27M | 2.27M | 2.27M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 210.92M | 170.32M | 207.82M | 460.07M | 459.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 266.50K | 266.50K | 266.50K |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 1.59M | 0.00 |
| Cash from Financing | 210.92M | 170.32M | 210.36M | 464.19M | 462.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.05M | -14.64M | -314.02M | 55.87M | 61.43M |